Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Perspiration

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44365   clinical trials with a EudraCT protocol, of which   7389   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Perspiration. Displaying page 1 of 1.
    EudraCT Number: 2020-006127-34 Sponsor Protocol Number: 1.3 Start Date*: 2021-09-17
    Sponsor Name:Verein zur Förderung der Wissenschaft und Forschung an der 1.Med. Abteilung der Krankenanstalt Rudolfstiftung
    Full Title: Empagliflozin as potential treatment option for postprandial hyperinsulinemic hypoglycaemia after bariatric surgery – a pilot study
    Medical condition: Postprandial hyperinsulinemic hypoglycaemia (PHH) typically occurs years after bariatric surgery and one to three hours after a carbohydrate-rich meal. It is caused by rapid gastric emptying of und...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024225-20 Sponsor Protocol Number: 301110_PALANCE Start Date*: 2014-08-22
    Sponsor Name:University Hospital Munich, Germany
    Full Title: The impact of phosphate balanced cristalloid infusion on acid-base homeostastis
    Medical condition: This study aims to investigate a new crystalloid fluid therapy regime for the perioperative setting providing stable fluid and acid-base homeostasis in the patient.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001972-36 Sponsor Protocol Number: CSOM230C2305 Start Date*: 2007-11-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, blinded study to assess the safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly.
    Medical condition: Acromegaly is characterized by chronic hypersecretion of growth hormone (GH), clinical features comprise structural and functional changes occurring in practically all organs. Cardiovascular diseas...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) BE (Completed) GB (Completed) GR (Completed) IT (Completed) ES (Completed) NL (Completed) DK (Completed) SE (Completed) HU (Completed) PL (Completed) PT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016722-13 Sponsor Protocol Number: CSOM230C2402 Start Date*: 2010-06-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III, multicenter, randomized, parallel-group study to assess the efficacy and safety of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open-label octreotide LAR or lanr...
    Medical condition: Acromegaly is characterized by chronic hypersecretion of growth hormone (GH), clinical features comprise structural and functional changes occurring in practically all organs. Cardiovascular diseas...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) IT (Completed) NO (Completed) BE (Completed) DE (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008135-28 Sponsor Protocol Number: 01-281108 Start Date*: 2009-04-16
    Sponsor Name:Hull and East Yorkshire NHS Hospitals Trust
    Full Title: Effect of Sildenafil on Pulmonary Artery Pressure during hypoxia and exercise in Chronic Heart Failure
    Medical condition: We will investigate the effect of sildenafil on pulmonary artery pressure in Heart failure patients (impaired heart function). Patients will be recruited from the Heart Failure clinic at Castle Hil...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002034 Anaemia LLT
    9.1 10040756 Sinusitis NOS LLT
    9.1 10016807 Fluid retention LLT
    9.1 10022437 Insomnia LLT
    9.1 10016998 Forehead headache LLT
    9.1 10010108 Common migraine LLT
    9.1 10002855 Anxiety LLT
    9.1 10044565 Tremor LLT
    9.1 10033987 Paresthesia LLT
    9.1 10006790 Burning sensation NOS LLT
    9.1 10020937 Hypoaesthesia LLT
    9.1 10007882 Cellulitis LLT
    9.1 10022000 Influenza LLT
    9.1 10038870 Retinal hemorrhage LLT
    9.1 10047544 Visual disturbance NOS LLT
    9.1 10047513 Vision blurred LLT
    9.1 10034960 Photophobia LLT
    9.1 10008795 Chromatopsia LLT
    9.1 10051819 Cyanopsia LLT
    9.1 10015910 Eye blood shot LLT
    9.1 10015946 Eye irritation LLT
    9.1 10038189 Red eye LLT
    9.1 10047531 Visual acuity reduced LLT
    9.1 10013036 Diplopia LLT
    9.1 10000173 Abnormal sensation in eye LLT
    9.1 10047340 Vertigo LLT
    9.1 10065027 Sudden deafness LLT
    9.1 10016825 Flushing LLT
    9.1 10006461 Bronchitis NOS LLT
    9.1 10015090 Epistaxis LLT
    9.1 10039092 Rhinitis NOS LLT
    9.1 10011224 Cough LLT
    9.1 10028735 Nasal congestion LLT
    9.1 10012735 Diarrhoea LLT
    9.1 10013946 Dyspepsia LLT
    9.1 10017869 Gastritis NOS LLT
    9.1 10017888 Gastroenteritis LLT
    9.1 10017885 Gastrooesophageal reflux disease LLT
    9.1 10019022 Haemorrhoids LLT
    9.1 10000060 Abdominal distension LLT
    9.1 10013781 Dry mouth LLT
    9.1 10001760 Alopecia LLT
    9.1 10015150 Erythema LLT
    9.1 10029410 Night sweats LLT
    9.1 10040913 Skin rash LLT
    9.1 10028411 Myalgia LLT
    9.1 10003988 Back pain LLT
    9.1 10018800 Gynaecomastia LLT
    9.1 10036661 Priapism LLT
    9.1 10052791 Erection increased (excl priapism) LLT
    9.1 10037660 Pyrexia LLT
    9.1 10042438 Sudden hearing loss, unspecified LLT
    9.1 10033425 Pain in extremity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Dec 13 16:16:26 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA